Show all news
  • microbiology
  • VelaLabs
  • analytical services
  • Bioassay
  • Biomolecules
  • Diabetes
  • pharmaceutical
  • Diabetes type I
  • Diabetes type II
  • FDA approval
  • Semglee

Bevacizumab patent protection expires soon

Jan 12, 2022

FACES OF CANCER

Over 100 types of cancer – a group of diseases involving abnormal cell growth with potential of invading and spreading into other parts of the body – affect about 100 million people worldwide, with over 8 million deaths anually. The risk of cancer increases with age and is more likely in developed countries, though with change of livestyle in developing countries, rates in these countries are also increasing.

While some environmental factors can be avoided to reduce the risk of cancer and there are some effective medications for high risk persons as well as vaccinations for some types of cancer, research concentrates on treatment therapies.

A variety of therapies are using immunotherapy to help the body fighting cancer. Approaches using antibodies came into use since 1997.

Bevacizumab (Avastin®)

The neutralizing antibody bevacizumab is one of the blockbusters in the treatment of cancer.

It inhibits tumor growth – one of the hallmarks of cancer – by binding to a growth factor called Vascular Endothelial Growth Factor (VEGF).

The patent protection of bevacizumab has expired in the US in 2019 and will expire in the EU in 2022. There are already some biosimilars on the market or approved. More biosimilars are in development. Examples for marketed biosimilars are Mvasi®, launched in 2019, and Zirabev®, launched in 2020.

VelaLabs provides different assays for binding analysis

For analysing the binding to different isoforms of VEGF we provide SPR technology, ELISA and also an anti-proliferation bioassay with HUVEC cells but also reporter gene assays are used.

With our services in analysis and characterization of biomolecules our experts are looking forward to answering your questions. 

Read more about biomolecules HERE.
International Agency for research on cancer HERE.

Contact us – we are looking forward to supporting your analysis needs

velabd@vela-labs.at  I   +43 189 059 7911.

We Value Your Privacy
We use cookies on our website. Some of them are essential, while others help us to analyze how this website is being used and to allow you to contact us through our website, i.e. use the chat widget. You can change your decision at any time.
We Value Your Privacy
Statistics
We use these technologies to analyze how this website is being used.
Name Google Analytics, Google Tag Manager
Provider Google Ireland Limited, Gordon House, Barrow Street, Dublin 4, Ireland
Purpose Cookie by Google used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy Policy https://policies.google.com/privacy
Cookie Name _ga, _gat, _gid
Cookie Expiry 2 years

 

Name LinkedIn Corporation
Provider LinkedIn Corporation, 605 W Maude Ave, Sunnyvale, CA 94085, USA
Purpose Cookie by LinkedIn used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy Policy https://www.linkedin.com/legal/privacy-policy
Cookie Name
Cookie Expiry 2 years
Customer Interaction
These technologies will allow you to contact us through our website, i.e. use the chat widget.
Name LiveChat
Provider LiveChat Software S.A., ul. Zwycięska 47, 53-033 Wroclaw, Poland
Purpose Communication with clients via online chat using the API of the chat service LiveChat.
Privacy Policy https://www.livechat.com/legal/privacy-policy/
Cookie Name __lc_cid, __lc_cst
Cookie Expiry 2 years
Essential
Technologies required to enable the core functionality of this website.
Name Cookie Consent
Provider Owner of this website, Imprint
Purpose Saves the visitors preferences selected in the cookie banner.
Cookie Name ws_cookie_consent
Cookie Expiry 1 year